tbuckley/cabot-search huggingface dataset:
332TiP SOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2+ metastatic breast cancer (MBC)
Authors: E.M. Ciruelos, S. Pernas, A. Perelló, A. Lopez, F.J. Salvador Bofill, J.M. Cejalvo, I. Blancas, J. Ponce Lorenzo, S. Servitja, M. Perez, J. Cruz, C. Albacar, S.I. Escrivá-de-Romaní, J.A. Guerra, S. González-Santiago, E. Sanfeliu, C. Rodriguez, P. Tolosa, J.M. Ferrero-Cafiero, A. Prat
Journal: Annals of Oncology (2021)
904P ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort
Authors: A.L. Ho, D.W. Bowles, C. Even, D. Hao, H. Kang, R. Metcalf, J. Muzaffar, M. Oliva, C.A. Perez, A. Popovtzer, C.P. Rodriguez, S.M. Stemmer, C.M. Van Herpen, E. Winquist, L.J. Wirth, F.P. Worden, B. Xia, G. Gordon, G.B. Gordon, R. Ferrarotto
Journal: Annals of Oncology (2021)
683P Impact of renin-angiotensin system inhibitors (RASi) on outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI)
Authors: P.V. Nuzzo, E. Adib, N. Weise, C. Curran, T. Stewart, D. Freeman, A.H. Nassar, S. Abou Alaiwi, Z. Bakouny, B.A. McGregor, T.K. Choueiri, R.K. Jain, R.R. McKay, G.P. Sonpavde
Journal: Annals of Oncology (2021)
583P Baseline plasma tumour DNA (ptDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide
Authors: V. Conteduca, E. Scarpi, D. Wetterskog, N. Brighi, G. Schepisi, A. Romanel, C. Casadei, C. Lolli, G. Gurioli, I. Toma, G. Poti, A. Farolfi, F. Demichelis, G. Attard, U. De Giorgi
Journal: Annals of Oncology (2021)
Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine
Authors: Zi‐Hang Chen, Li Lin, Chen‐Fei Wu, Chao‐Feng Li, Rui‐Hua Xu, Ying Sun
Journal: Cancer Communications (2021)

Abstract Over the past decade, artificial intelligence (AI) has contributed substantially to the resolution of various medical problems, including cancer. Deep learning (DL), a subfield of AI, is characterized by its ability to perform automated feature extraction and has great power in the assimilation and evaluation of large amounts of complicated data. On the basis of a large quantity of medical data and novel computational technologies, AI, especially DL, has been applied in various aspects of oncology research and has the potential to enhance cancer diagnosis and treatment. These applications range from early cancer detection, diagnosis, classification and grading, molecular characterization of tumors, prediction of patient outcomes and treatment responses, personalized treatment, automatic radiotherapy workflows, novel anti‐cancer drug discovery, and clinical trials. In this review, we introduced the general principle of AI, summarized major areas of its application for cancer diagnosis and treatment, and discussed its future directions and remaining challenges. As the adoption of AI in clinical use is increasing, we anticipate the arrival of AI‐powered cancer care.
317P Survival analysis and prognostic factors in patients with metastatic breast cancer and oligometastatic disease
Authors: G. Marin Zafra, E.G. Torralba, V. Garcia, P. de la Morena, M.J. Martinez Ortiz, E. Garcia, A. Ivars, B. Alvarez Abril, M. Sánchez Cánovas, E. Garcia Martinez, F. Ayala de la Peña
Journal: Annals of Oncology (2021)
LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial
Authors: J. Bourhis, Y. Tao, X. Sun, C. Sire, L. Martin, X. Liem, A. Coutte, Y. Pointreau, J. Thariat, J. Miroir, F. Rolland, M-C. Kaminsky, C. Borel, A. Maillard, L. Sinigaglia, J. Guigay, E. Saada-Bouzid, C. Even, A. Aupérin
Journal: Annals of Oncology (2021)
32P Observational study to compare in vitro sensitivity to therapy in patients-derived organoids (PDOs) with real life outcome: The ChemoSenPDO study
Authors: J. Garcias-Donas, Z. Dantes, B. Jiménez, M. Yagüe, A. Manjunath, L. Ferreira, B. Hefel, J. Slawska, J.F. Rodríguez-Moreno, E. Sevillano, A. Barquin, M. Dorta Suarez, J. Rodriguez Pascual, C. Millan, I. Lopez, L. Jimenez, A. Müller, M. Barba, S. Ruiz-Llorente, P. Navarro
Journal: Annals of Oncology (2021)
Transanal Drainage Tube Use for Preventing Anastomotic Leakage After Laparoscopic Low Anterior Resection in Patients With Rectal Cancer
Authors: Song Zhao, Luyang Zhang, Feng Gao, Miao Wu, Jianyong Zheng, Lian Bai, Fan Li, Baohua Liu, Zehui Pan, Jian Liu, Kunli Du, Xiong Zhou, Chunxue Li, Anping Zhang, Zhizhong Pu, Yafei Li, Bo Feng, Weidong Tong
Journal: JAMA Surgery (2021)

Preventing anastomotic leakage (AL) is crucial for colorectal surgery. Some studies have suggested a positive role of transanal drainage tubes (TDTs) in AL prevention after low anterior resection, but this finding is controversial.To assess the effect of TDTs in AL prevention after laparoscopic low anterior resection for rectal cancer.This multicenter randomized clinical trial with parallel groups (TDT vs non-TDT) was performed from February 26, 2016, to September 30, 2020. Participants included patients from 7 different hospitals in China who were undergoing laparoscopic low anterior resection with the double-stapling technique for mid-low rectal cancer; 576 patients were initially enrolled in this study, and 16 were later excluded. Ultimately, 560 patients were randomly divided between the TDT and non-TDT groups.A silicone tube was inserted through the anus, and the tip of the tube was placed approximately 5 cm above the anastomosis under laparoscopy at the conclusion of surgery. The tube was fixed with a skin suture and connected to a drainage bag. The TDT was scheduled for removal 3 to 7 days after surgery.The primary end point was the postoperative AL rate within 30 days.In total, 576 patients were initially enrolled in this study; 16 of these patients were excluded. Ultimately, 560 patients were randomly divided between the TDT group (n = 280; median age, 61.5 years [IQR, 54.0-68.8 years]; 177 men [63.2%]) and the non-TDT group (n = 280; median age, 62.0 years [IQR, 52.0-69.0 years]; 169 men [60.4%]). Intention-to-treat analysis showed no significant difference between the TDT and non-TDT groups in AL rates (18 [6.4%] vs 19 [6.8%]; relative risk, 0.947; 95% CI, 0.508-1.766; P = .87) or AL grades (grade B, 14 [5.0%] and grade C, 4 [1.4%] vs grade B, 11 [3.9%] and grade C, 8 [2.9%]; P = .43). In the stratified analysis based on diverting stomas, there was no significant difference in the AL rate between the groups, regardless of whether a diverting stoma was present (without stoma, 12 [5.8%] vs 15 [7.9%], P = .41; and with stoma, 6 [8.3%] vs 4 [4.5%], P = .50). Anal pain was the most common complaint from patients in the TDT group (130 of 280, 46.4%). Accidental early TDT removal occurred in 20 patients (7.1%), and no bleeding or iatrogenic colonic perforations were detected.The results from this randomized clinical trial indicated that TDTs may not confer any benefit for AL prevention in patients who undergo laparoscopic low anterior resection for mid-low rectal cancer without preoperative radiotherapy.ClinicalTrials.gov Identifier: NCT02686567.
585P Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Authors: C.N. Sternberg, S. Bracarda, J.S. de Bono, C. Sweeney, K.N. Chi, D. Olmos, S.K. Sandhu, C. Massard, J. Garcia, F. Schenkel, G. Chen, A. Harris, H. Hinton, N. Matsubara
Journal: Annals of Oncology (2021)
798P A phase II study of pembrolizumab (P) in combination with doxorubicin (D) in advanced endometrial cancer (AEC): TOPIC trial/VHIO10001
Authors: L. Fariñas-Madrid, M.J. Rubio, A. Redondo, G. Villacampa Javierre, A. Yubero Esteban, I. Romero, M. Gil-Martin, J. Garcia-Donas, A. González-Martín, A. Gallego Martinez, F. Grau, F. Ruiz-Pace, B. Pardo Búrdalo, M.L. Sanchez Lorenzo, J.M. Piulats, A. Oaknin
Journal: Annals of Oncology (2021)
100P Characteristics and outcomes of patients (pts) with NTRK fusion-positive (NTRK+) metastatic / locally advanced (LA) solid tumours receiving non-TRK inhibitor (TRKi) standard of care (SoC), and prognostic value of NTRK fusions in clinical practice
Authors: G.D. Demetri, S. Peters, D.P. Hibbar, J. Davies, S.L. Maund, L. Veronese, H. Liu, O. Humblet, L. Perez
Journal: Annals of Oncology (2021)
Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma
Authors: Sakiko Harada, Miki Ando, Jun Ando, Midori Ishii, Tomoyuki Yamaguchi, Satoshi Yamazaki, Tokuko Toyota, Kazuo Ohara, Manami Ohtaka, Mahito Nakanishi, Chansu Shin, Yasunori Ota, Kazutaka Nakashima, Koichi Ohshima, Chihaya Imai, Yozo Nakazawa, Hiromitsu Nakauchi, Norio Komatsu
Journal: Molecular Therapy (2021)

We generated dual-antigen receptor (DR) T cells from induced pluripotent stem cells (iPSCs) to mitigate tumor antigen escape. These cells were engineered to express a chimeric antigen receptor (CAR) for the antigen cell surface latent membrane protein 1 (LMP1; LMP1-CAR) and a T cell receptor directed to cell surface latent membrane protein 2 (LMP2), in association with human leucocyte antigen A24, to treat therapy-refractory Epstein-Barr virus-associated lymphomas. We introduced LMP1-CAR into iPSCs derived from LMP2-specific cytotoxic T lymphocytes (CTLs) to generate rejuvenated CTLs (rejTs) active against LMP1 and LMP2, or DRrejTs. All DRrejT-treated mice survived >100 days. Furthermore, DRrejTs rejected follow-up inocula of lymphoma cells, demonstrating that DRrejTs persisted long-term. We also demonstrated that DRrejTs targeting CD19 and LMP2 antigens exhibited a robust tumor suppressive effect and conferred a clear survival advantage. Co-operative antitumor effect and in vivo persistence, with unlimited availability of DRrejT therapy, will provide powerful and sustainable T cell immunotherapy.
Impact of Myocardial Injury in Hospitalized Patients With COVID-19 in 2 Peak Time Periods
Authors: Solomon W. Bienstock, Pranai Tandon, Usha Govindarajulu, Evan Leibner, Benjamin S. Glicksberg, Rajeev Samtani, Gennaro Giustino, Umesh Gidwani, Roopa Kohli-Seth, Martin E. Goldman
Journal: Journal of the American College of Cardiology (2021)
LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study
Authors: T.B. Powles, V. Chistyakov, V. Beliakouski, A. Semenov, E. Everaert, Y. Baranau, V. Moreno, B. Perez Valderrama, Y. Vano, G. Del Conte, Y. Loriot, T.W. Kang, M. Tammaro, A. O'Hagan, M. Hosseini, S. Triantos, H. Chhabra, A. Santiago-Walker, A.O. Siefker-Radtke
Journal: Annals of Oncology (2021)
Dissolving microneedle patches loaded with amphotericin B microparticles for localised and sustained intradermal delivery: Potential for enhanced treatment of cutaneous fungal infections
Authors: Ke Peng, Lalitkumar K. Vora, Ismaiel A. Tekko, Andi Dian Permana, Juan Domínguez-Robles, Delly Ramadon, Philip Chambers, Helen O. McCarthy, Eneko Larrañeta, Ryan F. Donnelly
Journal: Journal of Controlled Release (2021)
715P Nivolumab in pretreated metastatic penile squamous cell carcinoma: Results of the penile cohort from the French AcSé prospective program
Authors: D. Pouessel, M. Beylot-Barry, S.B. Esma, M. De Pontville, E. Coquan, H. Mahammedi, C. Gavoille, F. Ghiringhelli, O. Dereure, J-P. Spano, D. Tosi, A. Fléchon, D. Pannier, P. Augereau, L. Gambotti, F. Legrand, C. Simon, A. Lamrani-Ghaouti, S. Chevret, A. Marabelle
Journal: Annals of Oncology (2021)
319P A propensity score weighted study comparing two versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer
Authors: H. Bischoff, C. Bigot, F. Moinard, C. Pflumio, C. Fischbach, M. Kalish Weindling, M. Alt, L. Pierard, T. Petit, M.F. Demarchi, J.E. Kurtz, D. Karouby, P. Coliat, D. Cox, X. Pivot, L. Bender, P. Trensz
Journal: Annals of Oncology (2021)
1395P Impact of delay in adjuvant chemotherapy on survival in resected gastric cancer: Real world data from India
Authors: S. Arora, A. Sharma, R. Pramanik, V. Raina, S.V.S. Deo, S. Kumar, N.K. Shukla, S. Pal, N.R. Dash, S. Pathy, B.K. Mohanty
Journal: Annals of Oncology (2021)
596P Impact of combined lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)
Authors: B. Mak, H-M. Lin, E.M. Kwan, H. Fettke, B. Tran, I.D. Davis, K.L. Mahon, M.R. Stockler, K. Briscoe, G.M. Marx, M. Kohli, W. Tan, K. Huynh, P. Du, J. Yu, S. Jia, A.M. Joshua, A.A. Azad, P.J. Meikle, L.G. Horvath
Journal: Annals of Oncology (2021)
467P Monocyte to red blood cells ratio (MRR): an innovative haematologic prognostic parameter in FOLFIRI-aflibercept treated patients: A subgroup analysis from the DISTINCTIVE trial
Authors: E. Lai, S. Murgioni, P. Ziranu, D. Basile, S. Cherri, C. Madeddu, F. Bergamo, G. Piacentini, V. Smiroldo, M. Squadroni, M.C. De Grandis, L. Mascia, G. Rosati, M.G. Zampino, A. Spallanzani, V. Conca, M.A. Palladino, V. Flaminio, S. Di Bella, M. Scartozzi
Journal: Annals of Oncology (2021)
1378P A single-center, prospective, open-label, single-arm trial of sintilimab with paclitaxel and carboplatin as a neoadjuvant therapy for esophageal squamous carcinoma
Authors: Z. Zhang, J. Ye, H. Li, M. Du, D. Gu, J. Zhang, W. Chen, C. Xu, Y. Fang, J. Zhang, K. Zhao, G. Zhou
Journal: Annals of Oncology (2021)
Abstract 16830: Late Removal of a pLVAD Increases Mortality
Authors: Qi Chen, Mark Pollet, Adwait Mehta, Juliette Dean, Jennifer Parenti, Francia Rojas, Yutao Xi, Jie Cheng, Nilesh Mathuria
Journal: Circulation (2018)

Objective: The impact of the timing of removal of a percutaneous left ventricular assist device (pLVAD) during VT ablation on outcomes is uncertain. We compare the outcomes of patients with early (≤ 24 hours) versus late (&gt;24 hours) removal of pLVAD during VT ablation. Methods: We reviewed the data of 27 male patients who underwent VT ablation with pre-emptive pLVAD support between March 2013 to November 2017. There were 2 groups: (1) Early removal group: pLVAD was removed in ≤ 24 hours after VT ablation (n = 18), (2) Late removal group: pLVAD was removed &gt; 24 hours (n = 9). Results: There was no significant difference of age (67.33 ± 12.67 vs. 60.67 ± 14.93 yrs, p = 0.236), Diabetes (both 33.3%), ICMP (56% vs. 44%, p = 0.60), COPD (16.7% vs. 11.1%, p = 0.71), VT storm (both 22.2%), procedure duration (391.5 ± 70.76 vs. 395.67 ± 126.32 min, p = 0.912) between the 2 groups. There was a trend towards longer VT duration during the procedure in Group 2 (28.00 ± 27.16 vs. 60.4 ± 25.1 min, p = 0.148). The LVEF in group 1 is significantly higher (28.09% ± 9.44% vs. 20.00 ± 2.50%, p = 0.019). The 90-day mortality was higher in group 2 (11.1% vs. 44.4%, p = 0.025). Conclusions: Late removal (&gt;24 hours) of a pLVAD for VT ablation is associated with an increased 90-day mortality. Severely depressed LVEF and potentially prolonged time in VT may predict poorer outcomes despite pLVAD support. Figure 1 Kaplan-Meier Survival Curve of the patients with structural heart disease undergoing catheter ablation of ventricular tachycardia under the support of percutaneous left ventricular assist device (pLVAD) (group 1: patient had pLVAD removed ≤ 24 hours after VT ablation; group 2: patient had pLVAD removed &gt;24 hours after VT ablation)
693P Plasma exosome microRNA-155-3p expression in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: Potential biomarker of response to systemic therapy
Authors: M. Soleimani, M. Thi, N. Saxena, D.J. Khalaf, B.J. Eigl, K.N. Chi, C.K. Kollmannsberger, L. Nappi
Journal: Annals of Oncology (2021)
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
Authors: Hiddo J L Heerspink, Niels Jongs, Glenn M Chertow, Anna Maria Langkilde, John J V McMurray, Ricardo Correa-Rotter, Peter Rossing, C David Sjöström, Bergur V Stefansson, Robert D Toto, David C Wheeler, Tom Greene
Journal: The Lancet Diabetes & Endocrinology (2021)
1858P To use a digital clinical decision platform to improve efficiency in lung cancer multi-disciplinary tumorboard meeting
Authors: C-H. Lin, B-Y. Wang, S-H. Lin, S-L. Wang, J-C. KAO, W.C. Wang, P.H. Shih, C-W. Chiu, C-M. Lee, H-F. Liao, C-M. Chen, Y.T. Huang, S.C. Chen
Journal: Annals of Oncology (2021)
LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer
Authors: C. Saura Manich, J. O'Shaughnessy, P.G. Aftimos, E. van den Tweel, M. Oesterholt, S.I. Escrivá-de-Romaní, N. Quenel Tueux, T.J. Tan, J.S. Lim, S. Ladoire, A. Armstrong, T. Crook, A. Stradella, G. Bianchi, R. Mulder, N. Koper, N. Turner
Journal: Annals of Oncology (2021)
539P Interim results of a phase I study of M701, a recombinant anti-EpCAM and anti-CD3 bispecific antibody in EpCAM-positive cancer patients with malignant ascites
Authors: J. Xu, C. Zhao, Y. Jia, S. Wang, X. Ma, T. Wang, S. Huang, M. Pei, X. Wang, P. Zhou
Journal: Annals of Oncology (2021)
Alpelisib administration reduced lymphatic malformations in a mouse model and in patients
Authors: Florence Delestre, Quitterie Venot, Charles Bayard, Antoine Fraissenon, Sophia Ladraa, Clément Hoguin, Célia Chapelle, Junna Yamaguchi, Rubina Cassaca, Lola Zerbib, Sato Magassa, Gabriel Morin, Vahid Asnafi, Patrick Villarese, Sophie Kaltenbach, Sylvie Fraitag, Jean-Paul Duong, Christine Broissand, Olivia Boccara, Véronique Soupre, Bernard Bonnotte, Caroline Chopinet, Tristan Mirault, Christophe Legendre, Laurent Guibaud, Guillaume Canaud
Journal: Science Translational Medicine (2021)

Alplesib exerts therapeutic effects in a mouse model of lymphatic anomalies and in six patients with lymphatic malformations over 6 months’ treatment.
1491P Assessment of psychiatric disorder in patients with metastatic breast cancer: A cross-sectional study
Authors: R. Basto, C. Caramujo, I. Ferreira Gomes, T. Fraga, J. Correia Magalhães, M.J. Sousa, A.R. Monteiro, A. Pestana Santos, T. Carvalho, E. Albuquerque, G. Sousa
Journal: Annals of Oncology (2021)
1564MO Characterization of COVID-19 vaccination response by antibody (Ab) titer and T-cell receptor (TCR) sequencing in patients (pts) with advanced genitourinary (GU) cancers
Authors: S.K. Salgia, J. Malhotra, Z. Zengin, L. Meza, J. Ely, J. Hsu, E. Kelley, A. Chehrazi-Raffle, A. Govindarajan, R. Muddasani, N. Salgia, N. Dizman, N. Chawla, T. Dorff, Y. Lyou, E. Karczewska, J. Trent, R. Salgia, J. Altin, S.K. Pal
Journal: Annals of Oncology (2021)
665P Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101
Authors: M-O. Grimm, M. Oya, T.K. Choueiri, M. Schmidinger, D.I. Quinn, G. Gravis Mescam, E. Verzoni, A.J.M. Van den Eertwegh, A. di Pietro, M. Mariani, J. Wang, D. Thomaidou, L. Albiges
Journal: Annals of Oncology (2021)
231P Prognosis and efficacy of frontline treatment for HR+ HER2- metastatic breast cancer occurring in gBRCA1/2 carriers
Authors: J-S. Frenel, A. Lusque, S. Delaloge, J-M. Ferrero, T. Bachelot, I. Desmoulins, C. Levy, J-C. Eymard, A. Gonçalves, A. Patsouris, M.A. Mouret Reynier, M. Leheurteur, T. Petit, L. Cabel, L. Uwer, M. Debled, M. Chevrot, A. Mailliez, W. Jacot, T. De La Motte Rouge
Journal: Annals of Oncology (2021)
Effectiveness of a Psychosocial Aftercare Program for Youth Aged 8 to 17 Years With Severe Chronic Pain
Authors: Meltem Dogan, Gerrit Hirschfeld, Markus Blankenburg, Michael Frühwald, Rosemarie Ahnert, Sarah Braun, Ursula Marschall, Ingo Pfenning, Boris Zernikow, Julia Wager
Journal: JAMA Network Open (2021)

Severe chronic pediatric pain causes individual suffering and significantly affects social functioning and psychological well-being. For children with high pain severity, intensive interdisciplinary pain treatment (IIPT) is a well-established treatment. However, across specialized centers, it is not sufficient for all patients.To evaluate the effectiveness of a psychosocial aftercare (PAC) program for pediatric patients with severe chronic pain followed up for 6 months after discharge from IIPT.This multicenter randomized clinical trial with 4 assessment points (pre-IIPT, immediately post-IIPT, 3 months, and 6 months) was conducted at 3 pediatric specialized tertiary care pain centers in Germany between September 11, 2018, and March 31, 2020. Included patients were aged 8 to 17 with a severe chronic pain condition who had been admitted for IIPT. Data were analyzed from June 8 to September 4, 2020.Patients and their families were randomly assigned to 1 of 2 study groups at inpatient IIPT admission. Both groups received standardized 3- to 4-week IIPT. After IIPT discharge, the intervention group received PAC and the control group received usual care. PAC involved ongoing contact with a social worker for as long as the family requested the support, up to a maximum of 6 months.The primary outcome measure was pain at 6 months, measured using the Chronic Pain Grading (CPG), an instrument based on an algorithm indicating severity of the chronic pain disorder. Secondary outcomes included other pain-related and emotional parameters.A total of 419 patients were randomized (mean [SD] age, 14.3 [2.1] years; 303 [72.3%] girls; 116 [27.7%] boys), with 218 assigned to usual care and 201 assigned to PAC. At baseline in both groups, the median (IQR) CPG was 3 (2-4). Superiority of PAC compared with usual care was demonstrated at 6 months (median [IQR] CPG: usual care, 2 [2-3]; PAC, 1 [1-2]; r = 0.30; 95% CI, 0.17-0.41). Additionally, PAC significantly improved emotional parameters (eg, significant time × group interaction: b = -8.84; P < .001).This randomized clinical trial found that PAC improved pain-related and emotional parameters during the intervention 6 months after discharge from IIPT. Future research is needed to investigate the intervention's long-term effects.German Clinical Trials Register ID: DRKS00015230.
817TiP GYNET study - Safety and efficacy of anti-netrin 1 (NP137) in combination with chemotherapy and/or pembrolizumab in patients (pts) with pretreated locally advanced/metastatic endometrial carcinoma or cervix carcinoma: An adaptive multi-arms randomized phase I/II trial
Authors: I. Ray-Coquard, P. Cassier, S. Chabaud, P. Mehlen, A. Bernet, F. Le Bras, H. Gheit, C. Angel, C. Mastier, B. Ducarouge, T. De La Motte Rouge, L. Gladieff, A. Floquet, M. Fabbro, F. Joly, M. Provansal Gross, J-S. Frenel, A. Leary, D. Perol, J-Y. Blay
Journal: Annals of Oncology (2021)